Kefah Mokbel: Targeted Breast Cancer Therapies Linked to Increased Thrombotic Risk
Kefah Mokbel, Professor of Medicine at Cardiff University School of Medicine, Professor of Breast Cancer Surgery at Brunel University of London, Chair of Breast Cancer Surgery at The Princess Grace Hospital, shared a post on LinkedIn about a recent article by Wesley Boland et al, published in Research Square, adding:
“This real-world analysis demonstrates that CDK4/6i and everolimus were associated with increased risk of both arterial and venous thrombosis, while PARPi was specifically associated with venous thrombosis.
Similar risk was seen across CDK4/6 inhibitor agents.
All hazard ratios exceed 3.
These results support risk stratification tools incorporating both agent and patient-level factors to better inform clinical management.”
Title: Thrombotic Risk of Targeted Therapies in Breast Cancer: A Real-World Cohort Study
Authors: Wesley Boland, Gregory Guzik, Eduarda Grinsztejn, Jaime A Perez, Keri Plevniak, Bethany Samuelson Bannow, Lalitha Nayak, James Martin
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 26, 2026, 13:32Jorge Enrique: Beyond Fibrin Targeting New Strategies for Thrombolysis
-
Oct 26, 2026, 13:23Priya Sriskandarajah: Treatment Challenges in Elderly and Frail Patients with Philadelphia-Negative MPNs
-
Oct 26, 2026, 12:48Milica Kuzmanovska: Latest Updates in PV, ET, and Myelofibrosis Management
-
Oct 26, 2026, 12:38Hytham Abu Aagla: Daratumumab and Transfusion Compatibility
-
Oct 26, 2026, 10:17Pankaj K.: Genetic Hemolytic Anemias Common Types, Symptoms and Long-Term Management
-
Oct 26, 2026, 10:09Christopher Robinson: Anemia and Postpartum Transfusion Rates at Different Blood Loss Thresholds After Vaginal Delivery
-
Oct 26, 2026, 09:54Hussnain Javaid: IV Iron During Active Bacterial Infection Reassessing the Risks and Benefits
-
Oct 26, 2026, 09:37Fathima Zulfa Mohamed Sattar: Systematic Investigation of Bleeding Disorders and Coagulation Abnormalities
-
Oct 26, 2026, 09:12Robert Major: GFAP as a Point-of-Care Biomarker in Intracerebral Hemorrhage